GMDP and psoriasis.
Bhushan
M
M
McElhone
K
K
Griffiths
C E
CE
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000704:Analysis of Variance; D002908:Chronic Disease; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D017211:Treatment Failure
D000276:Adjuvants, Immunologic; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C063429:glucosaminylmuramyl-2-alanine-D-isoglutamine